Supplementary materialS Sample preparation
The tissue samples were flash-frozen in vaporphase liquid N 2 without an embedding agent, and were then stored at -80° C until subsequent analysis. At the time of tissue biopsy, a blood samples was collected from each patient in heparin-containing tubes, and centrifuged at 1500 × g at 4° C for 10 min to obtain the plasma, which was stored at -80° C until subsequent analysis. The frozen tissues were sliced into 8 μm thick slices at −20° C with a cryomicrotome (Leica CM 1950, Tokyo, Japan) into at least six serial sections, with the exception of one patient's paired samples (rash and normal skin tissues) that was insufficient in quantity for laser microdissection (LMD) and was cut into three serial sections. The first and third sections were used for liquid chromatographytandem mass spectrometry (LC-MS/MS) measurement of erlotinib concentration in the tissue, whereas the second section was placed on indium tin oxide-coated (ITO) glass slides (Matsunami Glass Ind., Ltd., Tokyo, Japan) and used for matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The BZ-X710 microscope (Keyence, Itasca, IL, USA) was used for the observation and calculation of the target tissue and infiltrating inflammatory cells areas. The fourth to sixth tissue sections were used for LC-MS/MS of erlotinib concentration in the small pieces that were cut off by LMD (Leica LMD 6500).
lC-mS/mS
Erlotinib was extracted from the plasma by solid phase extraction using Oasis HLB 96-well plates (10 mg sorbent per well, Waters, Milford, MA, USA). Erlotinib calibration standards ranging from 5 to 5000 ng/mL (linearity, R 2 = 0.9988) were prepared from standard solutions with human pooled plasma (Sigma-Aldrich, St. Louis, MO, USA), and used during the measurement of plasma erlotinib concentration (Supplementary Figure 8 , available online). Erlotinib-d6 was used as the internal standard (100 ng/mL). For erlotinib extraction from tissues, the sections were vortexed for 30 s in 100 µL of 30% acetonitrile, 10% isopropanol, and 0.1% formic acid (FA), and centrifuged at 120,000 × g for 10 min at 4° C, after which the supernatants were collected. A total of 20 µL supernatants and internal standard, 260 µL of 50% methanol and 0.1% FA were used for the quantitation of erlotinib, with calibration standards ranging from 0.5 to 100 ng/mL (linearity R 2 = 0.9994) (Supplementary Figure 9 , available online). Chromatographic separation of the erlotinib and erlotinib-d6 was performed using the XBridge C18 HPLC column (2.1 × 5.0 mm, 3.5 mm, Waters) maintained at 40° C. Mobile phases A and B consisted of 0.1% FA aqueous solution and acetonitrile containing 0.1% FA, respectively. Separation was performed using a gradient elution at a flow rate of 0.2 mL/min with a Nexera X2 series (Shimadzu, Co., Kyoto, Japan). The gradient elution of the two mobile phase systems with 0.1% FA aqueous (A) and acetonitrile containing 0.1% FA (B) was as follows: 20-65% B for 0-4.0 min, 65-90% B for 4.0-4.1 min, 90% B for 4.1-5.1 min and 90-20% B for 5.1-5.2 min, with a re-equilibrium time of 3 min. The column was equilibrated with the mobile phase for 10 min, with a run time of 8 min for each 1 µL (plasma sample) or 20 µL (tissue sample) injection volume. Quantitation was conducted by selected reaction monitoring on a QTRAP5500 (plasma sample) or QTRAP4500 (tissue sample) mass spectrometer (AB Sciex, Framingham, MA, USA) with electrospray ionization in the positive mode. The optimized electrospray ionization parameters were as follows: ion source temperature, 600° C; curtain gas, setting 50; nebulizing gas (GS1), setting 70; turboionspray gas (GS2), setting 80; ion spray voltage, 5000 V; declustering potential, 6 V; and collision energy, 33V. The selected reaction monitoring transitions were m/z 394.0 to 336.0 for erlotinib and m/z 400.0 to 338.9 for erlotinib-d6. The dwell time was 500 ms for each transition channel. All data were acquired and analyzed using the Analyst version 1.6.1 software (AB Sciex).
malDi-mSi
α-cyano-4-hydroxycinnamic acid (CHCA, Sigma) was coated on the dried section placed on the ITO glass slide using a vacuum sublimation apparatus (SVC-700TMSG/7PS80, SANYU Electron, Tokyo, Japan) at 250° C for 8 min, after which 10 mg/mL CHCA solution containing 30% acetonitrile, 10% isopropanol, and 0.1% FA was sequentially sprayed on the section using a sprayer (PS270, GSI Creos, Tokyo, Japan) in the following 10 cycles; the first three cycles were for 3 s with spraying at 90 s intervals, and the next seven cycles were for 1 s with spraying at 30 s intervals. To evaluate the ionization efficiency of erlotinib on the tissue sections and for adjustment of ionization efficiency between samples, erlotinib-d6 was used as the internal standard in the CHCA solution (2 mg/mL). MALDI-MSI was performed using the iMScope (Shimadzu; Kyoto, Japan), which consisted of an optical microscope and a quadrupole ion trap timeof-flight analyzer with an atmospheric pressure MALDI source consisting of a 335 nm Nd:YAG laser (minimum laser spot diameter <10 μm). The spatial resolution of this examination was at a step size of 60 mm (Supplementary Figure 10 , available online), and the erlotinib-d6 image was acquired with a 30 mm shift from the laser spot obtained with erlotinib. The optimized laser parameters were as follows: strength, setting 40; spot size, setting 2; number of shot, 50 shots; and frequency, 1,000 Hz. The optimized detector parameters were as follows; ion mode, positive; accumulation, 3 times/ pixel; sample voltage, 3.5 kV; detector voltage, 2.1 kV; MS/MS energy, 50%; gas volume, 50%, isolation time, 20 ms; and collision-induced dissociation time, 30 ms. Molecular images of erlotinib and erlotinib-d6 were acquired in tandem mass spectrometry and the optimal transitions were m/z 394.10 ± 3.0 [M + H] + to 336.15 ± 0.05 (mass range, m/z 100 to 396) for erlotinib, and m/z 400.10 ± 1.5 [M + H] + to 339.15 ± 0.05 (mass range, m/z 100 to 405) for erlotinib-d6. Raw molecular images of erlotinib and erlotinib-d6 were visualized using Imaging MS Solution (version 1.11, Shimadzu) with an absolute ion intensity scale (Supplementary Figure  4 , available online). Biomap version 3.8.0.4 (Novartis Institutes for BioMedical Research, Basel, Switzerland) was used to display the adjusted molecular image of erlotinib distribution (divided images of raw erlotinib image by erlotinib-d6 image). Scale bar of erlotinib molecular image was converted from absolute ion intensity to erlotinib concentration using the sum of ion intensity and the total quantity of erlotinib by LC-MS/MS analysis of the serial sections. We also employed Biomap software to extract the ion data in the regions of interests. Mass spectrometric experiments were partly performed by Shimadzu TechnoResearch (Tokyo, Japan).
immunohistochemistry and histological evaluation
Hematoxylin and eosin staining of tissue section was used for the observation of histological finding and calculation of the infiltrating inflammatory cells areas. Epidermal growth factor receptor (EGFR) staining was performed with BenchMark XT (Ventana Medical Systems/Roche Diagnostics, Tucson AZ, USA) using ultraVIEW Universal DAB Detection Kit (Ventana/ Roche) according to the manufacturer's instructions with EGFR (3C6) antibody (Ventana/Roche) (Supplementary Figure 3 , avaiable online). 
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